Cardiovascular co-morbidity in patients with COPD in Bulgaria

References

• GOLD 2019. [cited 2019 May]. Available from: http://goldcopd.org/wp-content/uploads/2017/11/GOLD-2010-v6.0-FINAL-revised-20-Nov_WMS.pdf.
   Google Scholar
• Antoniu SA. Reducing mortality for chronic obstructive pulmonary disease: role of statins and angiotensin-covering enzyme inhibitors. Exp Rev Parmacoecon Outcomes Res. 2009;9(6):523–525.
   PubMedGoogle Scholar
• Soriano JB, Visick GT, Muellerova H, et al. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest. 2005;128(4):2099–2107.
   PubMed Web of Science ®Google Scholar
• Fabbri LM, Luppi F, Beghe B, et al. Complex chronic comorbidities of COPD. Eur Respir J. 2008;31(1):204–212.
   PubMed Web of Science ®Google Scholar
• Trinkmann F, Saur J, Borggrefe M, et al. Cardiovascular comorbidities in chronic obstructive pulmonary disease (COPD)-current considerations for clinical practice. JCM. 2019;8(1):69.
   Web of Science ®Google Scholar
• Dalal AA, Shah M, Lunacsek O, et al. Clinical and economic burden of patients diagnosed with COPD with comorbid cardiovascular disease. Respir Med. 2011;105(10):1516–1522.
   PubMed Web of Science ®Google Scholar
• Maclay JD, McAllister DA, Macnee W. Cardiovascular risk in chronic obstructive pulmonary disease. Respirology. 2007;12(5):634–641.
   PubMed Web of Science ®Google Scholar
• Osmanliev D. COPD – Cardiovascular comorbidity and safety of beta 2 agonists with focus on the indacaterol. Thoracic Med. 2013;5(3):10–20.
   Google Scholar
• Hoiseth AD, Neukamm A, Karlsson BD, et al. Elevated high-sensitivity cardiac troponin T is associated with increased mortality after acute exacerbation of chronic obstructive pulmonary disease. Thorax. 2011; 66(9):775–781.
   PubMed Web of Science ®Google Scholar
• Finkelstein J, Cha E, Scharf SM. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. Int J Chron Obstruct Pulmon Dis. 2009;4:337–349.
   PubMedGoogle Scholar
• MacDonald MI, Shafuddin E, King PT, et al. Cardiac dysfunction during exacerbations of chronic obstructive pulmonary disease. Lancet Respir Med. 2016;4(2):138–148.
   PubMed Web of Science ®Google Scholar
• Buch P, Friberg J, Scharlin H, et al. Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study. Eur Respir J. 2003;21(6):1012–1016.
   PubMed Web of Science ®Google Scholar
• Houben-Wilke S, Jorres RA, Bals R, et al. Peripheral artery disease and its clinical relevance in patients with COPD in the COSYCONET Study. Am J Respir Crit Care Med. 2017;195(2):189–197.
   PubMed Web of Science ®Google Scholar
• Lopez-Sanchez M, Munoz-Esquerre M, Huertas D, et al. High prevalence of left ventricle diastolic dysfunction in severe COPD associated with a low exercise capacity: a cross-sectional study. PLoS One. 2013;8(6):e68034.
   PubMed Web of Science ®Google Scholar
• Institute for Health Metrics and Evaluation: Bulgaria. [cited Jan 2018]. Available from: http://www.healthdata.org/bulgaria.
   Google Scholar
• Kamusheva M, Dimitrova M, van Boven JFM, et al. Clinical characteristics, treatment patterns, and socio-economic burden of COPD in Bulgaria. J Med Econ. 2017;20(5):503–509.
   PubMed Web of Science ®Google Scholar
• Mekov E, Slavova Y, Tsakova A, et al. Cardiovascular risk assessment in COPD patients with severe exacerbation. Eur Respirat J. 2016;48:PA1134.
   Web of Science ®Google Scholar
• Pavlov P, Ivanov Y, Glogovska P, et al. Cardiovascular comorbidity and mortality in patients with chronic obstructive pulmonary disease. Eur Respirat J. 2012;40:P986.
   Web of Science ®Google Scholar
• Ni Y, Shi J, Wan H. Use of cardioselective β-blockers in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized, placebo-controlled, blinded trials. J Int Med Res. 2012;40(6):2051–2065.
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease—2007update. Can Respir J. 2007;14(Suppl. B):5B–32B.
   PubMed Web of Science ®Google Scholar
• Rabe KF, Hurst JR, Suissa S. Cardiovascular disease and COPD: dangerous liaisons? Eur Respir Rev. 2018;27(149):180057.
   PubMed Web of Science ®Google Scholar
• van Manen JG, Bindels PJ, IJzermans CJ, et al. Prevalence of comorbidity in patients with a chronic airway obstruction and controls over the age of 40. J Clin Epidemiol. 2001;54(3):287–293.
   PubMed Web of Science ®Google Scholar
• Mitsiki E, Bania E, Varounis C, et al. Characteristics of prevalent and new COPD cases in Greece: the GOLDEN study. Int J Chron Obstruct Pulmon Dis. 2015;10:1371–1382.
   PubMed Web of Science ®Google Scholar
• Müllerova H, Agusti A, Erqou S, et al. Cardiovascular comorbidity in COPD: systematic literature review. Chest. 2013;144(4):1163–1178.
   PubMed Web of Science ®Google Scholar
• Nagorni-Obradovic L, Vukovic D. The prevalence of COPD co-morbidities in Serbia: results of a national survey. NPJ Prim Care Respir Med. 2014;24:12020–14008.
   Web of Science ®Google Scholar
• Papaioannou AI, Bartziokas K, Loukides S, et al. Cardiovascular comorbidities in hospitalised COPD patients: a determinant of future risk? Eur Respir J. 2015;46(3):846–849.
   PubMed Web of Science ®Google Scholar
• Ivanov Y, Nikolaev I, Nemeth I. Real-life evaluation of COPD treatment in a Bulgarian population: a 1-year prospective, observational, noninterventional study. Int J Chron Obstruct Pulmon Dis. 2018;13:653–663.
   PubMed Web of Science ®Google Scholar
• Bocskei RM, Benczur B, Bikov A, et al. Cardiovascular risk detection in COPD. Eur Respir J. 2019;54:PA5016.
   Web of Science ®Google Scholar
• Soumagne T, Roche N, Guillien A, et al. Cardiovascular risk in COPD: Deciphering the contribution of tobacco smoking. Chest. 2020;157(4):834–845.
   PubMed Web of Science ®Google Scholar
• Hutchinson AF, Graco M, Rasekaba TM, et al. Relationship between health-related quality of life, comorbidities and acute health care utilisation, in adults with chronic conditions. Health Qual Life Outcomes. 2015;13:69.
   PubMed Web of Science ®Google Scholar
• Lee SD, Huang MS, Kang J, et al. Investigators of the Predictive Ability of CAT in Acute Exacerbations of COPD (PACE) Study. The COPD assessment test (CAT) assists prediction of COPD exacerbations in high-risk patients. Respirat Med. 2014;108(4):600–608.
   PubMed Web of Science ®Google Scholar
• Fragoso E, André S, Boleo-Tomé JP, et al. Understanding COPD: a vision on phenotypes, comorbidities and treatment approach. Rev Port Pneumol (2006). 2016;22(2):101–111.
   PubMed Web of Science ®Google Scholar
• Quint J. The Relationship between COPD and cardiovascular disease. Tanaffos. 2017; 16(Suppl 1):S16–S17.
   PubMedGoogle Scholar
• Bayar B, Kutkan NU, Yilmaz ES, et al. Cost evaluation of inhaler therapies used in respiratory diseases: 1998-2015 period in Turkey. Value Health Reg Issues. 2017;13:31–38.
   PubMedGoogle Scholar
• Morgan AD, Zakeri R, Quint JK. Defining the relationship between COPD and CVD: what are the implications for clinical practice. Ther Adv Respir Dis. 2018;12:1753465817750524
   Web of Science ®Google Scholar
• Juanes A, Garin N, Mangues MA, et al. Impact of a pharmaceutical care programme for patients with chronic disease initiated at the emergency department on drug-related negative outcomes: a randomised controlled trial. Eur J Hosp Pharm. 2018;25(5):274–280.
   PubMedGoogle Scholar
• Wang B, Li R, Lu Z, et al. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging. 2020; 12(7):6049–6057.
   PubMedGoogle Scholar